These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29963781)

  • 1. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
    Omori K; Nomoto H; Nakamura A; Takase T; Cho KY; Ono K; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 Mar; 10(2):367-374. PubMed ID: 29963781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
    Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
    Intern Med; 2016; 55(13):1697-703. PubMed ID: 27374668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
    Ballmann M; Hubert D; Assael BM; Staab D; Hebestreit A; Naehrlich L; Nickolay T; Prinz N; Holl RW;
    Lancet Diabetes Endocrinol; 2018 Feb; 6(2):114-121. PubMed ID: 29199116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
    Esposito K; Giugliano D; Nappo F; Marfella R;
    Circulation; 2004 Jul; 110(2):214-9. PubMed ID: 15197140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
    Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
    Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing hypoglycemia frequency using flash glucose monitoring in older Japanese patients with type 2 diabetes receiving oral hypoglycemic agents.
    Abe H; Shikuma J; Suwanai H; Sano K; Okumura T; Kan K; Takahashi T; Miwa T; Suzuki R; Odawara M
    Geriatr Gerontol Int; 2019 Oct; 19(10):1030-1035. PubMed ID: 31486247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
    Wang W; Bu R; Su Q; Liu J; Ning G
    Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
    Jovanovic L; Hassman DR; Gooch B; Jain R; Greco S; Khutoryansky N; Hale PM
    Diabetes Res Clin Pract; 2004 Feb; 63(2):127-34. PubMed ID: 14739053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
    Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
    Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
    Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.